Our previous studies highlighted the potential utility of combined BRAF/Src inhibition for preventing the emergence of Rac-driven BRAFi/MEKi-resistance in undifferentiated melanoma cell lines [14, 15]. This evidence concerns the gene AKT1 and melanoma.